Company Filing History:
Years Active: 2016
Title: The Innovative Contributions of Chantale Bernatchez
Introduction
Chantale Bernatchez is a prominent inventor based in Spring, TX (US). She has made significant strides in the field of immunotherapy, particularly in the development of T-cell therapies for cancer treatment. Her work focuses on enhancing the efficacy of T cells in targeting tumors, which is crucial for advancing cancer therapies.
Latest Patents
Chantale holds a patent for a groundbreaking invention titled "B and T lymphocyte attenuator marker for use in adoptive T-cell therapy." This patent describes the role of BTLA-positive ('BTLA+') lymphocyte signaling in driving T cells to kill tumors. The BTLA functions as a positive modulator of anti-tumor T cell responses, particularly against melanoma. Her research indicates that BTLA+ T cells respond more effectively to interleukin-2 (IL-2) than their BTLA-negative counterparts. This discovery positions BTLA-positive T cells as a valuable marker for selecting enriched anti-tumor reactive T cells, which can be utilized in adoptive T-cell therapy for therapeutic purposes.
Career Highlights
Chantale is affiliated with the University of Texas System, where she continues her research and development in immunotherapy. Her innovative approach to T-cell therapy has the potential to transform cancer treatment and improve patient outcomes.
Collaborations
Chantale has collaborated with notable colleagues in her field, including Laszlo Radvanyi and Patrick Hwu. Their combined expertise contributes to the advancement of cancer therapies and the understanding of immune responses.
Conclusion
Chantale Bernatchez's contributions to the field of immunotherapy exemplify the impact of innovative research on cancer treatment. Her patent and ongoing work at the University of Texas System highlight her commitment to improving therapeutic strategies for cancer patients.